Skip to main content
. 2016 Apr 26;7(28):43124–43149. doi: 10.18632/oncotarget.8988

Figure 5. Effect of Sulindac sulfide treatment on fibronectin-mediated invasion (A), levels of active beta-catenin (B) and expression/function of MMP7, a transcriptional target of active beta-catenin (C) in different TNBC cells.

Figure 5

A. Sulindac sulfide (50 μM) blocked fibronectin-mediated invasion of MDA-MB231, MDA-MB468 and SUM149 TNBC cells through matrigel in the transwell invasion assay (**p< 0.05; ***p< 0.0001; *p< 0.07). B. Sulindac sulfide dose-dependently (25 μM and 50 μM) blocked the transcriptionally active form of beta-catenin in MDA-MB468, SUM149, HCC70 and MDA-MB231 TNBC cells. The expression of active beta-catenin was semi-quantified using ImageJ. C. Sulindac sulfide dose-dependently (25 μM and 50 μM) decreased both the levels of the MMP7 protein as well as its function (casein zymogram from secreted MMP7 in the conditioned media) in HCC70 and SUM149 TNBC cells. The expression of MMP7 protein was semi-quantified using ImageJ.